Individuals with Bipolar Disorder Have a Higher Level of Homocysteine Than Major Depressive Disorder: A Retrospective Chart Review and Observational Study
Miao Zhao,Tengteng Liu,Sufang Qi,Wenjie Li,Xin Liu,Xinming Li,Guanglei Xun
DOI: https://doi.org/10.2147/NDT.S387063
IF: 2.989
2022-11-15
Neuropsychiatric Disease and Treatment
Abstract:Miao Zhao, Tengteng Liu, Sufang Qi, Wenjie Li, Xin Liu, Xinming Li, Guanglei Xun Department of Psychiatry, Shandong Mental Health Center, Shandong University, Jinan, People's Republic of China Correspondence: Guanglei Xun, Department of Psychiatry, Shandong Mental Health Center, Shandong University, No. 49 Wenhua Eastern Road, Jinan, People's Republic of China, Tel +86 15069053599, Email ; Purpose: Previous studies suggest that homocysteine (Hcy) may be involved in the pathogenesis of bipolar disorder (BD) and major depressive disorder (MDD) by influencing glutamatergic transmission, inflammation, and other mechanisms. There are no established biomarkers to distinguish BD from MDD. This study aims to compare Hcy levels between BD and MDD. Patients and Methods: We collected medical records of patients aged 14– 75 admitted to the hospital from January 1 to July 1, 2022 with a discharge diagnosis of MDD or BD, including all examinations of patients at admission (acute phase) and discharge (non-acute phase). We measured Hcy levels in healthy controls (HC). Results: The analysis included 104 patients with MDD, 103 patients with BD, and 80 HC. Hcy levels were higher in the MDD and BD group than in the HC group and higher in the BD group than in the MDD group, both in the acute and non-acute phases (all P 0.05). Multivariate logistic regression analysis only for the MDD and BD group indicated that the likelihood of BD diagnosis was significantly associated with Hcy levels (in the acute phase: OR = 1.052, P = 0.016; in the non-acute phase: OR = 1.101, P < 0.001) after controlling for gender, age, and metabolic indicators. Conclusion: Our study suggests that Hcy levels were elevated in MDD and BD patients and were higher in BD patients than in MDD patients, which provides evidence for a possible relationship between one-carbon metabolism and the pathogenesis of BD. Besides, Hcy may be one of the potential biomarkers to distinguish BD from MDD. Keywords: affective disorder, biomarker, pathophysiology, differential diagnosis In clinical practice, it is challenging to distinguish bipolar disorder (BD) from major depressive disorder (MDD) because the early onset of BD is often characterized by depressive episodes, which seem similar to MDD. 1 The misdiagnosis of patients with BD may lead to subsequent use of a single antidepressant rather than combining mood stabilizers, which can cause BD individuals to switch to mania, hypomania, or recurrent episodes of depression. 2 A recent study suggested that demographics, clinical characteristics, and several validated, easy-to-use screening tools (for example, using the Mood Disorder Questionnaire) can help clinicians improve the ability to identify patients with BD. 3 However, most tools still find it difficult to distinguish BD and MDD patients efficiently, and there are rarely laboratory indicators or imaging techniques diagnosing BD or distinguishing BD and MDD. Significantly, compared with adults, clinical presentations of adolescents are atypical, which makes the diagnosis of the pediatric-adolescent population remain a challenge. 4 Homocysteine (Hcy) is known as a sulfur-containing amino acid produced during methionine metabolism, 5 which is degraded via the remethylation pathway or trans-sulfuration pathway. In one-carbon metabolism, folate is converted to 5-methyltetrahydrofolate (5-methylTHF) by methylenetetrahydrofolate reductase (MTHFR), and then 5-methylTHF is used by methionine synthase and vitamin B12 to remethylate Hcy into methionine. 6 Thus, decreased MTHFR activity or deficiencies of folic acid or B12 may contribute to elevated Hcy levels. Hcy is degraded to cysteine during the trans-sulfuration pathway, and in most organizations, Hcy is either remethylated or exported out of the cell. 7 Hcy was found to induce hyperactivity in rats, which may be involved in the pathogenesis of attention deficit hyperactivity disorder (ADHD). 8 As a mixed excitatory agonist at the N-methyl-D-aspartate (NMDA) receptor, Hcy affects glutamatergic transmission. 9–12 Moreover, research published recently found that mood stabilizers may act on BD by inhibiting glutamatergic neurotransmission. 13 The metabolism of Hcy may have some relationship with BD. In addition, elevated Hcy levels promote its neurotoxic effects by several studied mechanisms, including mitochondrial dysfunction, oxidative stress induction, inflammation, mediated neuronal apoptosis, and aberrant DNA methylation. 14–18 These pathwa -Abstract Truncated-
psychiatry,clinical neurology